Inventor · disambiguated record
Simon Guile
Also filed as: GUILE SIMON · GUILE SIMON D · GUILE SIMON DAVID
15 granted patents·13 pending applications·204 citations·filing 1998–2014
93Inventor score
Files withASTRAZENECA AB16ASTRAZENECA UK LTD5GUILE SIMON DAVID3HARDERN DAVID2ASTRAZENECA AB A SWEDEN CORP1
Top patents by PatentIndex Score
28 records- 0193US7250419B2Trisubstituted triazolopyrimidines for use in platelet aggregation inhibitionASTRAZENECA AB·Filed 2005·Granted Jul 31, 2007·16 cites·14 claims
- 0292US6525060B1Triazolo(4,5-d)pyrimidine compoundsASTRAZENECA UK LTD·Filed 1999·Granted Feb 25, 2003·59 cites·14 claims
- 0390US6251910B11,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonistsASTRAZENECA UK LTD·Filed 1998·Granted Jun 26, 2001·55 cites·14 claims
- 0489US6974868B2CompoundsASTRAZENECA AB·Filed 2002·Granted Dec 13, 2005·20 cites·2 claims
- 0583US7064126B2CompoundsASTRAZENECA AB·Filed 2004·Granted Jun 20, 2006·17 cites·11 claims
- 0681US6713483B1[1,2,3]-triazolo[4,5-d] pyrimidine compoundsASTRAZENECA AB·Filed 2000·Granted Mar 30, 2004·16 cites·20 claims
- 0777US7964616B2Compounds 679ASTRAZENECA AB·Filed 2008·Granted Jun 21, 2011·3 cites·15 claims
- 0873US7384950B2Thienopyrimidinediones and their use in the modulation of autoimmune diseaseASTRAZENECA AB·Filed 2002·Granted Jun 10, 2008·7 cites·12 claims
- 0972US7393854B2Thienopyrimidinedinones and their use in modulation of autoimmune diseaseASTRAZENECA AB·Filed 2004·Granted Jul 1, 2008·5 cites·17 claims
- 1071US2010069408A1Trisubstituted triazolopyrimidines for use in platelet aggregation inhibitionASTRAZENECA AB·Filed 2009·Application pending·0 cites
- 1168US2008214812A1Trisubstituted triazolopyrimidines for use in platelet aggregation inhibitionASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 1268US2015152111A1Trisubstituted triazolopyrimidines for use in platelet aggregation inhibitionASTRAZENECA UK LTD·Filed 2014·Application pending·0 cites
- 1366US7384951B2Thienopyrimidinediones and their use in the modulation of autoimmune diseaseASTRAZENECA AB·Filed 2004·Granted Jun 10, 2008·2 cites·14 claims
- 1466US2014296258A1Trisubstituted triazolopyrimidines for use in platelet aggregation inhibitonASTRAZENECA UK LTD·Filed 2013·Application pending·0 cites
- 1565US7034032B2Cyclopentan-2-ol-1-yl-[1,2,3]triazolo[4,5-D]pyrimidine compoundsASTRAZENECA AB·Filed 2001·Granted Apr 25, 2006·2 cites·16 claims
- 1664US2007265282A1Novel compoundsASTRAZENECA AB·Filed 2007·Application pending·0 cites
- 1764US2013109702A1Trisubstituted triazolopyrimidines for use in platelet aggregation inhibitionASTRAZENECA AB·Filed 2012·Application pending·0 cites
- 1862US6844348B22,3,4-cyclopentan-2,3,4-triol-1-yl compoundsASTRAZENECA AB·Filed 2001·Granted Jan 18, 2005·1 cites·15 claims
- 1962US2013072503A1Trisubstituted triazolopyrimidines for use in platelet aggregation inhibitionHARDERN DAVID·Filed 2012·Application pending·0 cites
- 2061US8106073B2Quinoline derivatives 057GUILE SIMON DAVID·Filed 2008·Granted Jan 31, 2012·1 cites·7 claims
- 2161US2012165348A1Novel compoundsHARDERN DAVID·Filed 2011·Application pending·0 cites
- 2256US7345047B2Substituted [1,2,3]triazolo[4,5-d]pyrimidinesASTRAZENECA AB·Filed 2004·Granted Mar 18, 2008·0 cites·16 claims
- 2354US2008207642A1Thienopyrimidinediones and Their Use in the Modulation of Autoimmune DiseaseREYNOLDS RACHEL HEULWEN·Filed 2008·Application pending·0 cites
- 2451US2006223809A1Novel compoundsASTRAZENECA AB A SWEDEN CORP·Filed 2006·Application pending·0 cites
- 2551US2008214579A1Thienopyrimidinediones and their use in the modulation of autoimmune diseaseGUILE SIMON DAVID·Filed 2008·Application pending·0 cites
- 2651US2008221131A1Thienopyrimidinediones and their use in modulation of autoimmune diseaseGUILE SIMON DAVID·Filed 2008·Application pending·0 cites
- 2747US2008058309A1Novel Compounds 171ASTRAZENECA AB·Filed 2007·Application pending·0 cites
- 2835USRE46276ETriazolo(4,5-D)pyrimidine compoundsASTRAZENECA UK LTD·Filed 1999·Granted Jan 17, 2017·0 cites·23 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →